Rapid RV/LV

by RapidAI (formerly iSchemaView)  · Based in United States → — AI-powered rapid assessment of pulmonary embolism severity.
Cardiology Pulmonology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor for pricing information.
Regulatory Status Disclosed

Overview

Rapid RV/LV by RapidAI is an FDA-cleared artificial intelligence (AI) software designed to assist physicians in the rapid assessment of pulmonary embolism (PE) severity. It analyzes volumetric Computed Tomography Pulmonary Angiography (CTPA) acquisitions to automatically measure the maximal diameters of the right and left ventricles of the heart and report their ratio for adult patients. This tool is a key component of the broader Rapid PE solution, enabling healthcare teams to quickly conduct risk stratification for patients exhibiting right heart strain. By providing annotated images with ventricular measurements within minutes of a scan, Rapid RV/LV aims to reduce inter-rater variability and streamline the PE care pathway from diagnosis through treatment.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered analysis of CTPA images
  • Automated measurement of right and left ventricle diameters
  • Calculation of RV/LV ratio
  • Annotated images showing ventricular measurements
  • Rapid results (within minutes of scan)
  • Reduces inter-rater variability
  • Integration with Rapid PE solution
  • Triage and notification capabilities (as part of the broader Rapid platform)
  • DICOM viewer for AI outputs and source imaging (via Rapid mobile app)
  • Secure sharing of time-critical scans (via integration with communication apps)

Use Cases

  • Risk stratification for pulmonary embolism (PE) patients with right heart strain
  • Assessing pulmonary embolism severity
  • Expediting diagnosis and treatment plans for PE
  • Identifying patients who would benefit from further PE treatment
  • Streamlining PE care pathways
  • Supporting clinical decision-making in acute PE cases

What Physicians Need to Know

Evidence Base
Rapid RV/LV leverages the established clinical significance of the right ventricle to left ventricle (RV/LV) ratio as a key indicator of pulmonary embolism (PE) severity and right heart strain. The assessment of RV function, including the RV/LV ratio, is supported by guidelines such as the 2019 European Society of Cardiology for risk stratification in PE. Computerized Tomography Pulmonary Angiography (CTPA), which the tool analyzes, is the dominant imaging modality for suspected PE and is endorsed by the American College of Radiology and European Society of Cardiology Guidelines.
Clinical Validation Studies
The Rapid RV/LV software received U.S. FDA 510(k) clearance in February 2023. Algorithm development involved 516 CTPA cases from multiple sites, with 80% used for validation and 20% for training, covering a wide range of LV diameters. Validation testing demonstrated accurate representation of key processing parameters. Studies indicate excellent agreement between manual and automated RV/LV ratio measurements in acute PE, with a mean discrepancy of less than 2.5 mm, and the automated ratio is effective in predicting central clot burden. The technology also reduces inter-rater variability by standardizing ventricle diameter measurements. A meta-analysis showed that an increased RV/LV ratio had a sensitivity of 83% and specificity of 75% for identifying RV dysfunction on echocardiography, with an AUC of 0.86.
Override Rate Data
Specific override rate data for Rapid RV/LV is not publicly available in the provided search results.
Differential Diagnosis Support
Rapid RV/LV provides objective measurement of the RV/LV ratio from CTPA, which is crucial for risk stratification of pulmonary embolism patients with right heart strain. By quickly identifying significant right heart strain, the tool aids in confirming the severity of PE and helps differentiate it from other conditions that may present with similar symptoms, thereby guiding appropriate treatment pathways.
Guideline Update Frequency
The tool's core functionality is based on established clinical indicators (RV/LV ratio for PE severity) that are integrated into cardiology and pulmonary guidelines. As an AI-powered solution, updates to its algorithms would typically be part of the vendor's continuous improvement and maintenance cycle, aligning with evolving clinical evidence and best practices, though a specific frequency is not stated.
Clinical Workflow Integration
Rapid RV/LV is designed for seamless integration into the clinical workflow, automatically analyzing CTPA scans and calculating the RV/LV ratio within minutes. It generates annotated images and summary reports with the RV/LV ratio, delivering them directly to the Picture Archiving and Communication System (PACS). This integration with the broader Rapid PE solution, including triage, notification, and communication tools (mobile and web apps), streamlines the care pathway, accelerates patient triage, and reduces time to treatment for PE patients.
Decision Audit Trail
While not explicitly detailed for Rapid RV/LV, clinical decision support tools, especially those with FDA clearance and used in critical care pathways, are generally expected to maintain audit trails for data access and decision points to ensure regulatory compliance and quality assurance.
Physician Tip

Rapid RV/LV offers a critical, rapid, and objective assessment of the RV/LV ratio from CTPA, which is invaluable for immediate risk stratification of PE patients with suspected right heart strain. Leverage this tool to accelerate triage and treatment decisions, particularly in high-acuity settings. The standardized measurement reduces inter-rater variability, providing consistent data. Remember that while the tool provides crucial data, it should always be used in conjunction with comprehensive clinical assessment and judgment. Integrate its output with the broader Rapid PE solution for enhanced team communication and coordinated care.

Rapid RV/LV is a component of the Rapid PE solution by RapidAI. It integrates directly with PACS for automated image analysis and report delivery. The tool also works in conjunction with RapidAI's triage, notification, and workflow products, accessible via mobile and web applications, to streamline communication and care coordination. General EMR integration is a capability offered by the RapidAI platform.

Details

Category Cardiology AI, Radiology & Imaging AI
Pricing Contact vendor for pricing information. — Contact vendor for details.
DeploymentOn-premises (dedicated server or virtual machine) or hybrid (on-premises/cloud with secure link to cloud), connecting to hospital LAN/firewall.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Rapid RV/LV received FDA 510(k) clearance (K223396) on February 1, 2023. It is intended to measure maximal right and left ventricle diameters from CTPA acquisitions and report their ratio for adults, aiding in PE severity assessment.
Integrations
EHR Not specified
Specialties Cardiology, Pulmonology, Radiology

What the Web Says

Rapid RV/LV by RapidAI is an AI-powered tool designed to quickly assess the severity of pulmonary embolism (PE) by automatically calculating the right ventricle (RV) to left ventricle (LV) ratio from CT pulmonary angiograms (CTPA) within minutes. This rapid assessment helps physicians with risk stratification for patients with right heart strain, aiming to reduce time to diagnosis and standardize RV/LV measurements. While primarily focused on PE, RapidAI also offers solutions for stroke detection, demonstrating superior accuracy in identifying large vessel occlusions (LVOs) and medium vessel occlusions (MeVOs) compared to competitors like Viz.ai.

Overall: Positive

Strengths

  • Quickly identifies patients with possible right heart strain in PE cases.
  • Reduces time to diagnosis for pulmonary embolism.
  • Reduces variability and standardizes RV/LV measurement.
  • Superior accuracy in detecting LVOs and MeVOs in stroke patients compared to competitors.
  • Provides real-time alerts to the care team, streamlining communication and decision-making in stroke care.
  • Cloud-based with on-premise redundancy for continuous operation during connectivity issues or cyber security incidents.

Limitations

  • Limited information available specifically on physician, healthcare IT, and tech reviewer opinions for Rapid RV/LV, with much of the available data coming from press releases and studies by RapidAI or related entities.
  • Some studies suggest that experienced human readers can identify LVOs and MVOs with higher accuracy than RapidAI software in a real-world setting for stroke detection.
  • The impact of RapidAI on many patient-important outcomes, such as harms, mortality, quality of life, and length of hospital stay, is uncertain due to limitations in available evidence for stroke detection.
  • Cost-effectiveness of RapidAI for stroke detection is currently unknown.
  • General RapidAI employee reviews mention a 'horrible executive team' and instances of medical leave for mental abuse, though these are not specific to the RV/LV product.
  • Compared to broader AI solutions, Rapid RV/LV is a highly specialized tool focused exclusively on PE severity assessment, which might be a limitation for organizations seeking a multi-indication platform.

Based on reviews from: Respiratory Therapy, NCBI Bookshelf, NeurologyLive, RapidAI (Press Release), PMC, Reddit (r/Radiology, r/askCardiology, r/Cardiology, r/daddit, r/IntensiveCare), BioWorld, HealthAidb, Indeed.com, YouTube (Healthcare IT Today, Undercover RV Shopper), Radiology Partners, MDPI, Physician AI Tools

Last updated: 2026-07-20

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Rapid RV/LV

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Business Wire
RapidAI Enhances Pulmonary Embolism Care Solution with FDA 510(k) Clearance for Rapid RV/LV
RapidAI announced FDA 510(k) clearance for Rapid RV/LV, an AI-powered tool that quickly calculates the right ventricle to left ventricle ratio from CT pulmonary angiograms, aiding in the assessment of pulmonary embolism severity.
2023-02
BioWorld
Rapidai expands pulmonary embolism care with Rapid RV/LV clearance | BioWorld
RapidAI received FDA 510(k) clearance for Rapid RV/LV, an AI-driven solution that calculates the right ventricle to left ventricle ratio from CT pulmonary angiograms to help prioritize pulmonary embolism cases.
2023-02
Diagnostic Imaging
AI/CT Combination for Assessing Pulmonary Embolism Severity Gets FDA Nod
RapidAI's Rapid RV/LV, an AI-powered tool for expedited calculation of the right ventricle/left ventricle ratio to determine pulmonary embolism severity, has received FDA 510(k) clearance.
2023-02
AuntMinnie
FDA clears RapidAI's pulmonary embolism software - AuntMinnie
The U.S. Food and Drug Administration (FDA) has cleared RapidAI's Rapid RV/LV, a software program that calculates heart metrics associated with pulmonary embolism, specifically the right ventricle to left ventricle ratio.
2023-02
BioWorld
Rapidai reels in $75M in series C funds to expand AI clinical support platform | BioWorld
RapidAI secured $75 million in Series C funding to expand its AI clinical support platform, following its FDA 510(k) clearance for Rapid RV/LV in February.
2023-07
RapidAI
RapidAI Wins MedTech Breakthrough Award for Best New Imaging Solution
RapidAI's hemorrhagic solution, Rapid ICH and Rapid Hyperdensity, won the 'Best New Imaging Solution' award, with the company also highlighting recent FDA clearances for Rapid PE Triage & Notification, Rapid RV/LV, and Rapid NCCT Stroke.
2023-05
Guided Solutions
Editor's Choice: What Happened in 2023 in MedTech - Hiring Success - Guided Solutions
RapidAI received FDA 510(k) clearance for Rapid RV/LV at the end of February 2023, enhancing its Rapid PE solution by providing physicians with a tool to quickly assess the right ventricle to left ventricle ratio, a key indicator of pulmonary embolism severity.
2024-04
Frontiers in Cardiovascular Medicine
Artificial intelligence in cardiac amyloidosis: Expert insights on adoption challenges, opportunities and best practices for developing
A review of FDA-authorized AI tools relevant to cardiovascular applications as of January 5, 2025, includes Rapid RV/LV by iSchemaView Inc. (RapidAI) for RV/LV Ratio in Pulmonary Embolism using CT Pulmonary Angiograms, cleared in 2023.
2025-05

Videos

Product demos, reviews, and walkthroughs for Rapid RV/LV.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

Rapid RV/LV refers to AI-powered software solutions that automatically calculate the right ventricle to left ventricle (RV/LV) ratio from computed tomography pulmonary angiograms (CTPAs) within minutes. This tool helps physicians quickly assess right heart strain, a critical indicator for risk stratification in patients with suspected pulmonary embolism (PE), thereby streamlining the diagnostic and treatment pathway.
Rapid RV/LV solutions are designed to integrate with existing hospital systems, such as PACS, by providing annotated images and concise summary reports directly to the patient study. Companies like RapidAI and Viz.ai have received FDA 510(k) clearance for their RV/LV tools, indicating they meet regulatory standards for medical devices.
The primary benefits include significantly reducing the time to diagnosis and standardizing RV/LV measurements, which can otherwise be subject to inter-rater variability. This automation allows for faster patient prioritization and accelerated decision-making, especially crucial in acute conditions like pulmonary embolism.
While highly beneficial, AI-derived RV/LV measurements are not intended for use as a stand-alone basis for clinical decision-making and should always be part of a comprehensive clinical assessment. The complex geometry of the right ventricle can still pose challenges for accurate measurement across all modalities, and optimal cut-off values for clinical deterioration are continually being refined.
Alternative methods include bedside echocardiography, which offers quick identification of RV dysfunction, and cardiac MRI (CMR), considered the gold standard for comprehensive RV function assessment due to its accuracy and reproducibility. Invasive catheter assessment is also available, and newer echocardiographic techniques like 3D echocardiography and strain imaging are emerging for more detailed evaluation.
While specific pricing for Rapid RV/LV solutions is not readily available, AI-enhanced diagnostic tools generally show potential for long-term cost-effectiveness, particularly in outpatient settings for early disease detection. These technologies can potentially reduce overall healthcare costs by enabling earlier intervention and improving patient outcomes.
Rapid RV/LV provides an immediate, objective measure of right heart strain, which is a key indicator of pulmonary embolism severity. An RV/LV ratio greater than 1.0 is associated with a high risk of morbidity and mortality, allowing clinicians to quickly identify high-risk PE patients who may benefit from more aggressive treatment strategies.

Compare Rapid RV/LV

VS
Rapid RV/LV vs PMcardio
Cardiology AI Adjacent · 65/100
Rapid RV/LV and PMcardio are both cardiology AI tools, but they focus on different diagnostic modalities and conditions. Rapid RV/LV analyzes CTPA scans to assess pulmonary embolism severity…
VS
Rapid RV/LV vs EchoNext
Cardiology AI Adjacent · 65/100
Both Rapid RV/LV and EchoNext are FDA-cleared AI tools in cardiology, but they focus on different diagnostic modalities and conditions. Rapid RV/LV specializes in analyzing CTPA scans for…
VS
SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION vs Rapid RV/LV
Cardiology AI Adjacent · 65/100
Tool A, SensiCardiac Mobi, is designed to assist in diagnosing heart murmurs by analyzing acoustic heart signals from electronic stethoscopes. In contrast, Tool B, Rapid RV/LV, focuses on…
VS
Rapid RV/LV vs IM007
Cardiology AI Adjacent · 65/100
Tool A is an AI-powered solution for rapid assessment of pulmonary embolism severity by analyzing CTPA scans, focusing on acute diagnostic support. In contrast, Tool B is a…

Related Tools

Cardiomatics
Cardiomatics
Cardiology AI
Cardiomatics is a cloud-based, AI-powered software for analyzing ambulatory (Holter) ECG tests, using clinically validated algorithms to provide accurate and high-quality results for cardiac diagnostics. It aims to streamline ECG analysis, reduce interpretation time, and improve diagnostic accuracy for various heart conditions.
Paid, credit-based or subscription
SafeBeat Rx App
SafeBeat Rx, Inc.
Cardiology AI
An AI application designed to support safe pharmacological treatment and monitoring for cardiac arrhythmias.
PreemptiveAI Clinical SDK
Measure Labs, Inc. (Dba Preemptiveai, Inc.)
Cardiology AI
A clinical software development kit using AI to model and predict cardiovascular health metrics, aiming to shift healthcare from reactive to proactive by providing early health risk signals.
Clarius Ejection Fraction AI
Clarius Mobile Health Corp.
Cardiology AI
Clarius Ejection Fraction AI is an AI-powered ultrasound tool for automated left ventricular ejection fraction calculation, integrated into the Clarius Ultrasound App for real-time cardiac assessments.
Contact for pricing
Automated Aortic Stenosis Software (AutoAS)
Multiple companies are developing Automated Aortic Stenosis Software (AutoAS) or similar AI-powered solutions. Notable ones include iCardio.ai, Us2.ai, AccurKardia, HeartSciences Inc., and Echo IQ.
Cardiology AI
Automated Aortic Stenosis Software (AutoAS) is an ultrasound application by GE Medical Systems that provides automated assessment of aortic stenosis to enhance diagnostic efficiency and consistency.
ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm
Anumana
Cardiology AI
An AI algorithm that analyzes standard 12-lead ECG recordings to detect signs of pulmonary hypertension, aiming for earlier diagnosis and improved patient outcomes.

See all Cardiology AI tools →

More from RapidAI (formerly iSchemaView)

iSchemaView RAPID
RapidAI (formerly iSchemaView)
Neurology AI
RapidAI is an AI-enabled software platform that facilitates the viewing, processing, and analysis of CT and MRI imaging to aid clinicians in assessing patients with suspected stroke, providing automated results for faster, more accurate diagnostic and treatment decisions.
Contact for pricing
Rapid
RapidAI (formerly iSchemaView)
Neurology AI
RapidAI is an AI-driven medical imaging analysis and coordinated care platform that empowers healthcare teams to rapidly, precisely, and confidently manage life-threatening conditions, especially acute stroke, through advanced CT and MRI image processing.
Contact for pricing
Rapid CTA 360
RapidAI (formerly iSchemaView)
Neurology AI
Rapid CTA 360 by RapidAI (formerly iSchemaView) is an AI-powered imaging solution providing automated 3D CTA reconstructions for rapid and precise stroke diagnosis and treatment planning, enhancing visibility of occlusions and collateral flow.
Contact vendor for pricing
Rapid LVO
RapidAI (formerly iSchemaView)
Neurology AI
Rapid LVO by RapidAI is an FDA-cleared AI tool for the fast and accurate detection of Large Vessel Occlusions (LVOs) in acute stroke patients using CTA imaging, streamlining triage and care coordination.
Contact vendor for pricing.

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.